{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-069464","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2023-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.049485+00:00","generated_at":"2026-06-14T05:05:16.407389+00:00","sec_items":["5.02","5.07"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Director Todd Foley resigns; stockholders elect Kim, Zeiher to board, ratify EY","bullets":["Todd Foley resigned from the Board effective June 7, 2023; no disagreement with company operations.","At 2023 Annual Meeting, Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. elected as Class II directors.","Votes: Kim 24,512,848 for, Zeiher 24,696,429 for; broker non-votes of 1,876,971 each.","Ratification of EY as independent auditor for FY2023 passed: 26,634,250 for, 606 against, 10 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-069464","json":"https://secwatch.observer/filing/0001104659-23-069464.json","markdown":"https://secwatch.observer/filing/0001104659-23-069464.md","text":"https://secwatch.observer/filing/0001104659-23-069464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465923069464/0001104659-23-069464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465923069464/tm2318297d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:05:16.407389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"537bba29ec","claim":"Todd Foley resigned as member of the Board of Directors at Entrada Therapeutics, Inc..","evidence_excerpt":"On June 7, 2023, Todd Foley notified Entrada Therapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”), effective as of June 7, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465923069464/0001104659-23-069464-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the Board of Directors"}],"fact_type":"executive_change"},{"claim_id":"3ebd398dc3eb0eb40c0d2c04a4331b77220fadde","claim":"Entrada Therapeutics, Inc. shareholders approved Election of two Class II directors at the 2023-06-08 meeting.","evidence_excerpt":"Proposal No. 1 Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. were duly elected to the Company’s Board as Class II directors. The results of the election were as follows: CLASS II DIRECTOR NOMINEE FOR WITHHELD BROKER NON-VOTES Peter S. Kim, Ph.D. 24,512,848 245,047 1,876,971 Bernhardt Zeiher, M.D. 24,696,429 61,466 1,876,971","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465923069464/0001104659-23-069464-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"6de84b36f9d9a61fc4ac77891d6aba7be7e2e57a","claim":"Entrada Therapeutics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-08 meeting.","evidence_excerpt":"Proposal No. 2 The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The results of the ratification were as follows: FOR AGAINST ABSTAIN 26,634,250 606 10","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465923069464/0001104659-23-069464-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}